Enasidenib
Enasidenib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Myelodysplastic Syndrome。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
13 项
全球在招研究
1 项
已进入 III/IV 期
9 个
开展国家和地区
暂未检索到
中国境内设点
药品与企业信息
研发企业
- National Cancer Institute (NCI)
- Washington University School of Medicine
- Beat AML, LLC
- M.D. Anderson Cancer Center
- Gustave Roussy, Cancer Campus, Grand Paris
- Alice Mims
- Abramson Cancer Center at Penn Medicine
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、加拿大、Puerto Rico、丹麦、法国、意大利、荷兰、西班牙、英国
正在招募患者的 Enasidenib 研究
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
II 期招募中美国加拿大Puerto RicoNCT05564390Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial
II 期招募中美国NCT06240754Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
II 期 / III 期招募中美国NCT03013998Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
II 期招募中美国NCT03683433European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
I 期 / II 期招募中丹麦法国意大利荷兰NCT02813135Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
II 期招募中美国Puerto RicoNCT06577441IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
II 期招募中美国NCT05401097Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
II 期招募中美国NCT03383575Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
II 期招募中美国Puerto RicoNCT06672146Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
I 期 / II 期招募中美国NCT04774393Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
II 期招募中美国NCT06176989Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
I 期招募中美国NCT05010772Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
不适用招募中美国NCT03680677
中国患者怎么争取用上这款药
目前境内暂未检索到设点，下面几条途径是更现实的选择，每条都有详细的中文做法。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。